NasdaqGM:OCUL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. More Details


Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Ocular Therapeutix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OCUL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: OCUL's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

-9.4%

OCUL

-1.1%

US Pharmaceuticals

-2.7%

US Market


1 Year Return

310.7%

OCUL

6.1%

US Pharmaceuticals

21.2%

US Market

Return vs Industry: OCUL exceeded the US Pharmaceuticals industry which returned 9.2% over the past year.

Return vs Market: OCUL exceeded the US Market which returned 24.3% over the past year.


Shareholder returns

OCULIndustryMarket
7 Day-9.4%-1.1%-2.7%
30 Day-11.6%5.3%1.8%
90 Day90.0%16.0%16.4%
1 Year310.7%310.7%9.7%6.1%23.9%21.2%
3 Year229.6%229.6%27.2%17.2%43.7%34.2%
5 Year208.2%208.2%55.3%36.9%124.3%99.2%

Long-Term Price Volatility Vs. Market

How volatile is Ocular Therapeutix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ocular Therapeutix undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OCUL ($18.03) is trading below our estimate of fair value ($51.97)

Significantly Below Fair Value: OCUL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OCUL is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: OCUL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OCUL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OCUL has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Ocular Therapeutix forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

59.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCUL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: OCUL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OCUL's is expected to become profitable in the next 3 years.

Revenue vs Market: OCUL's revenue (38.4% per year) is forecast to grow faster than the US market (10.6% per year).

High Growth Revenue: OCUL's revenue (38.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OCUL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Ocular Therapeutix performed over the past 5 years?

-18.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OCUL is currently unprofitable.

Growing Profit Margin: OCUL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OCUL is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare OCUL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: OCUL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Ocular Therapeutix's financial position?


Financial Position Analysis

Short Term Liabilities: OCUL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: OCUL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: OCUL has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: OCUL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OCUL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OCUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Ocular Therapeutix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OCUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OCUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OCUL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OCUL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OCUL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Antony Mattessich (53 yo)

3.5yrs

Tenure

US$2,126,146

Compensation

Mr. Antony Mattessich has been the Chief Executive Officer and President of Ocular Therapeutix, Inc. since July 26, 2017. Mr. Mattessich serves as Managing Director of Mundipharma International Limited. He...


CEO Compensation Analysis

Compensation vs Market: Antony's total compensation ($USD2.13M) is below average for companies of similar size in the US market ($USD3.86M).

Compensation vs Earnings: Antony's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Antony Mattessich
President3.5yrsUS$2.13m0.13%
$ 1.8m
Patricia Kitchen
Chief Operating Officer1.58yrsUS$1.13m0%
$ 0
Michael Goldstein
President of Ophthalmology & Chief Medical Officer3.33yrsUS$1.01m0.044%
$ 592.6k
Donald Notman
Chief Financial Officer3.33yrsUS$982.03k0.032%
$ 433.7k
Peter Jarrett
Chief Scientific Officerno datano datano data
Philip Strassburger
General Counsel0.33yrno datano data
William Ransone
Vice President of Global Sales & Marketingno datano datano data
Christopher White
Senior Vice President of Business & Corporate Development2yrsno datano data
Tracy Smith
Vice President of Human Resources0.33yrno datano data
Scott Corning
Senior Vice President of Commercial3yrsno datano data
Rabia Ozden
Senior Vice President of Clinical Developmentno datano datano data
Eric Ankerud
Consultant & Senior Advisor3.42yrsUS$337.56kno data

3.0yrs

Average Tenure

53yo

Average Age

Experienced Management: OCUL's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Antony Mattessich
President3.5yrsUS$2.13m0.13%
$ 1.8m
Charles Warden
Independent Chairman1.42yrsUS$139.52k0%
$ 0
Richard Lindstrom
Independent Director8.17yrsUS$104.52k0.13%
$ 1.8m
Bruce Peacock
Lead Independent Directorno dataUS$117.02k0%
$ 0
Leslie Williams
Independent Director1.83yrsUS$144.47k0.0060%
$ 81.2k
Jeffrey Heier
Independent Director5.33yrsUS$96.44k0.032%
$ 432.7k
Seung Hong
Independent Director1.58yrsUS$124.02k0%
$ 0

2.7yrs

Average Tenure

60yo

Average Age

Experienced Board: OCUL's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 56.6%.


Top Shareholders

Company Information

Ocular Therapeutix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ocular Therapeutix, Inc.
  • Ticker: OCUL
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.358b
  • Shares outstanding: 75.30m
  • Website: https://www.ocutx.com

Number of Employees


Location

  • Ocular Therapeutix, Inc.
  • 24 Crosby Drive
  • Bedford
  • Massachusetts
  • 1730
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OCULNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2014
0OTDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2014

Biography

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel pl...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/28 01:06
End of Day Share Price2021/01/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.